SCNX_OUT_1 [2025-04-04 04:36:47 -0400] 3733 Bytes | 1047 tokens | Cum: 1047 tkns (13.09% of 8k)
==========================================================================

We need a winner today and it's already 4:36:46 AM on Fri Apr 04, 2025 -0400 ... So let's find out if Scienture (SCNX) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 1.32 up from 1.04. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Scienture (SCNX)
IPO: 2008-02-22 (17 Years Ago)
Market Cap: $12,047,380
Shares Outstanding: 12,520,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.

Here’s the first list of news for Scienture:

C1 - Apr-03-25 08:26AM - Scienture Holdings, Inc. Issues Annual Letter to Shareholders
C2 - Mar-25-25 08:05AM - SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization
C3 - Mar-19-25 08:05AM - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
C4 - Mar-18-25 08:05AM - SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.
C5 - Mar-06-25 07:40AM - SCIENTURE to commercially launch REZENOPY , a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
C6 - Jan-21-25 08:05AM - Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics
C7 - Dec-17-24 08:05AM - Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025
C8 - Dec-10-24 08:05AM - Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Prior AI Reports for SCNX:
1. 2025-04-01 – Score: 20 – Target: 1.6600 – Highs: 1.4800 / 1.3458 / 1.22
company-faces-severe-financial-distress-amid-drastic-sales-decline
2. 2025-03-21 – Score: 20 – Target: 2.0800 – Highs: 2.1600 / 2.0600 / 2.00
scienture-holdings-struggles-amidst-sharp-sales-decline-and-negative-earnings
3. 2025-03-19 – Score: 1 – Target: 1.8905 – Highs: 2.0693 / 1.9000 / 2.16
challenging-outlook-amid-signs-of-investor-interest

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Scienture (SCNX).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

SCNX_OUT_3 [2025-04-04 04:36:50 -0400] 1099 Bytes | 313 tokens | Cum: 1363 tkns (17.04% of 8k)
==========================================================================

Showing C1 (chunk 1 of 13): C1:
**Scienture Holdings, Inc. Issues Annual Letter to Shareholders**
Date: Apr-03-25 08:26AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/03/3055160/0/en/Scienture-Holdings-Inc-Issues-Annual-Letter-to-Shareholders.html

April 03, 2025 08:26 ET| Source:Scienture Holdings, Inc.Scienture Holdings, Inc.

TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX)a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to provide this annual update from its Chief Executive Officer, Surendra Ajjarapu, to its stockholders.

This time last year, Scienture Holdings, Inc. (f.k.a. TRxADE Health, Inc.). was focused on he

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCNX_OUT_5 [2025-04-04 04:36:51 -0400] 958 Bytes | 272 tokens | Cum: 1709 tkns (21.36% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-03T12:47:05Z - Scienture Holdings, Inc. Issues Annual Letter to Shareholders...
A2 - 2025-04-03T12:43:43Z - Scienture Holdings (SCNX) Issues Annual Letter to Shareholders...
A3 - 2025-04-03T12:33:37Z - Scienture Holdings, Inc. Issues Annual Letter to Shareholders | Taiwan News | Apr. 3, 2025 20:26...
A4 - 2025-03-25T12:27:32Z - SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a l...
A5 - 2025-03-25T12:27:53Z - SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a l...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SCNX_OUT_7 [2025-04-04 04:36:54 -0400] 1101 Bytes | 300 tokens | Cum: 2011 tkns (25.14% of 8k)
==========================================================================

Showing A1 (chunk 1 of 17): A1:
**Scienture Holdings, Inc. Issues Annual Letter to Shareholders**Date: 2025-04-03Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/03/tmt-newswire/globenewswire/scienture-holdings-inc-issues-annual-letter-to-shareholders/2086010Notification of managers and closely related parties' transactions with A.P. Møller - Mærsk A/S shares

TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to provide this annual update from its Chief Executive Officer, Surendra Ajjarapu, to its stockholders.

This time last year, S

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCNX_OUT_9 [2025-04-04 04:36:55 -0400] 440 Bytes | 120 tokens | Cum: 2213 tkns (27.66% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-21T13:05:00Z - Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SCNX_OUT_11 [2025-04-04 04:36:59 -0400] 848 Bytes | 243 tokens | Cum: 2458 tkns (30.73% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/21/3012635/0/en/Scienture-Holdings-Inc-Announces-Dr-Narasimhan-Mani-s-Participation-in-the-8th-Annual-Conference-of-The-Society-for-the-Study-of-Xenobiotics.htmlScienture Holdings, Inc., a specialty pharmaceutical company, announced that its President, Dr. Narasimhan Mani, will participate as a speaker and panelist at the 8th Annual Conference of The Society for the Study of Xenobiotics in India.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCNX_OUT_13 [2025-04-04 04:37:00 -0400] 1057 Bytes | 266 tokens | Cum: 2827 tkns (35.34% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-25 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER ##TABLE_END

The following discussion of the Companys historical performance and financial condition should be read together with the CONS financial statements and related notes...

S2 - 2025-03-25 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER ##TABLE_END

The following discussion of the Companys historical performance and financial condition should be read together with the CONS financial statements and related notes...

S3 - 2025-03-21 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 17, 2025, Scienture Holdings, Inc., a Delaware corporation (the Company) entered into a consulting agreement (the Consulting Agrmt) with Draper, Inc., a Nevada corporation (Draper). Pursuant to the Consulting A...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SCNX_OUT_15 [2025-04-04 04:37:00 -0400] 1098 Bytes | 235 tokens | Cum: 3064 tkns (38.30% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ##TABLE_END

The following discussion of the Companys historical performance and financial condition should be read together with the consolidated financial statements and related notes in the section entitled Item 8. Financial Statements and Supplemental Data of this Annual Report. This discussion contains forward-looking statements based on the views and beliefs of our management, as well as assumptions and estimates made by our management. See the section entitled Cautionary Statement Regarding Forward-Looking Information above. These statements by their nature are subject to risks and uncertainties and are influenced by various factors. As a consequence, actual results may differ materially from those in the forward-looking statements. See Item 1A. Risk Factors of this Annual Report for

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCNX_OUT_17 [2025-04-04 04:37:05 -0400] 1098 Bytes | 221 tokens | Cum: 3287 tkns (41.09% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): the discussion of risk factors. For all periods presented, the consolidated statements of income and consolidated balance sheet data have been adjusted for the reclassification of discontinued operations information, unless otherwise noted. All references to years relate to the calendar year ended December 31 of the particular year.

Summary of The Information Contained in Managements Discussion and Analysis of Financial Condition and Results of Operations

Our Managements Discussion and Analysis of Financial Condition and Results of Operations (MDA) is provided in addition to the accompanying consolidated financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. MDA is organized as follows:

##TABLE_START Company Overview . Discussion of our business and overall analysis of financial and other highlights affectin

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCNX_OUT_19 [2025-04-04 04:37:18 -0400] 4807 Bytes | 1307 tokens | Cum: 4700 tkns (58.75% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 505,210 | Perf Month: -52.73% | Option/Short: No / Yes | Sales Y/Y TTM: -98.47% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 2.90M | Perf Quarter: -83.23% | Short Float: 5.63% | ROE: -45.84% |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.17 | Index: - | Short Ratio: 0.12 | ROI: -25.83% |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 32.99 | Market Cap: 13.02M | Short Interest: 0.36M | Sales Surprise: 9.28% |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.38 | Shs Outstand: 8.75M | Beta: 2.74 | EPS Surprise: -286.67% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: -34.09% | Shs Float: 6.43M | Sales Q/Q: -97.74% | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: -59.57% | Inst Own: 0.75% | Sales past 5Y: -17.00% | Earnings: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -85.10% | Insider Own: 48.62% | Employees: 19 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: -36.97% | Insider Trans: 0.00% | Debt/Eq: 0.04 | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading if any are accessible.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 136643, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 9065798.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.04
Average Volume: 7914650.27
30-Day High: 2.48
30-Day Low: 1.04

[Detailed Financials: TTM 2024]
- Total Assets: $104,853,805.0
- Total Liabilities: $25,781,684.0
- Total Equity: $79,072,121.0
- Current Assets: $6,305,477.0
- Current Liabilities: $7,906,893.0

[Income Statement: TTM 2024]
- Revenue: $136,643.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 2.69

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $307,782

[Detailed Financials: FY 2024]
- Total Assets: $104,853,805.0
- Total Liabilities: $25,781,684.0
- Total Equity: $79,072,121.0
- Current Assets: $6,305,477.0
- Current Liabilities: $7,906,893.0

[Income Statement: FY 2024]
- Revenue: $136,643.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 2.69

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $307,782
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

SCNX_OUT_21 [2025-04-04 04:37:20 -0400] 687 Bytes | 169 tokens | Cum: 5212 tkns (65.15% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

SCNX_IN_23 [2025-04-04 04:37:20 -0400] 126 Bytes | 29 tokens | Cum: 5271 tkns (65.89% of 8k)
==========================================================================

====================================
[2025-04-04 04:37:20] # Analysis Completed
Elapsed Time: 34.05 seconds